The ORR was 62.5% (95% CI 35.4–84.8) among patients with EGFR-expressing tumours and 66.7% (95% CI 43.0–85.4) among those whose tumours were negative for EGFR expression. The gene discussed is EGFR; the disease is neoplasm.